Viatris launches Hulio (adalimumab biosimilar) in Canada

18 February 2021 - Viatris announced today that Health Canada has approved Hulio, and product is now available in Canada. ...

Read more →

Sandoz Canada completes its fifth biosimilar launch with new biosimilar Hyrimoz (adalimumab)

16 February 2021 - Hyrimoz for use in nine indications covered by the reference medicine in the fields of rheumatology, gastro-enterology ...

Read more →

Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima SC, for the treatment of people with rheumatoid arthritis

1 February 2021 - This novel formulation provides an alternative administration option for Canadian physicians and their patients. ...

Read more →

Sandoz Canada receives authorisation from Health Canada to launch new biosimilar Hyrimoz (adalimumab)

17 December 2020 - Hyrimoz approved for use in all same indications as reference medicine* including rheumatology, gastro-enterology and dermatology. ...

Read more →

Valeo Pharma announces Health Canada approval for Redesca and Redesca Hp

9 December 2020 - Valeo Pharma announced today that Health Canada has issued a Notice of Compliance for Redesca and ...

Read more →

Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo and Riximyo

9 June 2020 - These two approvals mark an important milestone for Sandoz Canada, bringing its biosimilars into oncology at a ...

Read more →

Valeo Pharma announces filing of a new drug submission for low molecular weight heparin in Canada

14 November 2019 - Valeo Pharma announced today that the new drug submission filed for a low molecular weight heparin ...

Read more →

Canada OKs Celltrion's biosimilar

10 September 2019 - Celltrion said that Health Canada has given the go-ahead for Herzuma (trastuzumab), an anticancer antibody biosimilar, ...

Read more →

Health Canada updates its biosimilar fact sheet

4 September 2019 - Health Canada recently updated its fact sheet on biosimilars, including new or clarified information about key ...

Read more →

Health Canada approves Mylan and Biocon's Ogivri, the first trastuzumab biosimilar, for the treatment of HER2-positive breast and gastric cancers

22 May 2019 - Ogivri is a part of Mylan's robust portfolio of 20 biosimilar and insulin analog products. ...

Read more →

Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan in Canada for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis

10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance  for Truxima (rituximab), the ...

Read more →

Patient access to cost-effective treatments increased with launch of new biosimilar in Canada

28 February 2019 - First-ever pegfilgrastim biosimilar approved by Health Canada launches across the country. ...

Read more →

Diverging from FDA, Health Canada announces suffix-free biologic and biosimilar naming convention

18 February 2019 - Health Canada has announced that all biologics, including biosimilars, will be identified by their brand names and ...

Read more →

Tanvex submits new drug submission for TX01 to Health Canada

[:content [\B \a \c \k \space \o \n \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \8 \, \space \t \h \e \space \U \S \space \F \D \A \space \a \c \c \e \p \t \e \d \space \T \a \n \v \e \x \space \B \i \o \P \h \a \r \m \a \’ \s \space \b \i \o \l \o \g \i \c \s \space \l \i \c \e \n \s \e \space \a \p \p \l \i \c \a \t \i \o \n \space \f \o \r \space \T \X \- \0 \1 \space \( \f \i \l \g \r \a \s \t \i \m \) \, \space \a \space \p \r \o \p \o \s \e \d \space \b \i \o \s \i \m \i \l \a \r \space \t \o " ..."]]
Read more →

Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the treatment of psoriatic arthritis in adult patients

21 January 2019 - Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic ...

Read more →